WS Investor
13 Jul 2026, 15:18
Biogen (BIIB) Stock Advances After Truist Upgrades Shares to Buy and Raises Price Target
Biogen (NASDAQ: BIIB) shares gained about 1.6% after Truist Financial upgraded the biotechnology company to Buy from Hold and raised its price target to $235 from $190.
The upgrade reflects growing confidence in Biogen's long-term growth outlook as investors look beyond legacy multiple sclerosis products and focus on the company's expanding neuroscience portfolio. Recent progress across Alzheimer's disease, rare diseases, and other neurological treatments has strengthened expectations for future revenue growth.
Biogen has also continued to improve its financial profile through disciplined cost management while advancing newer therapies that could diversify its earnings base over the coming years.
Key factors supporting the stock include:
* Truist Financial upgraded Biogen to Buy from Hold.
* The firm raised its price target to $235 from $190.
* Investors remain optimistic about the company's expanding neuroscience pipeline and long-term growth opportunities.
* Continued portfolio diversification and operational discipline are expected to support future earnings.
The analyst upgrade reinforced positive sentiment toward Biogen's evolving business strategy, helping lift the stock during the session.
Biogen (NASDAQ: BIIB) shares gained about 1.6% after Truist Financial upgraded the biotechnology company to Buy from Hold and raised its price target to $235 from $190.
The upgrade reflects growing confidence in Biogen's long-term growth outlook as investors look beyond legacy multiple sclerosis products and focus on the company's expanding neuroscience portfolio. Recent progress across Alzheimer's disease, rare diseases, and other neurological treatments has strengthened expectations for future revenue growth.
Biogen has also continued to improve its financial profile through disciplined cost management while advancing newer therapies that could diversify its earnings base over the coming years.
Key factors supporting the stock include:
* Truist Financial upgraded Biogen to Buy from Hold.
* The firm raised its price target to $235 from $190.
* Investors remain optimistic about the company's expanding neuroscience pipeline and long-term growth opportunities.
* Continued portfolio diversification and operational discipline are expected to support future earnings.
The analyst upgrade reinforced positive sentiment toward Biogen's evolving business strategy, helping lift the stock during the session.
